Skip to content

Abstract 10544: Dose-Dependent Outcomes of Direct Oral Anticoagulants for Extended Secondary Prevention of Venous Thromboembolism: A Bayesian Network Meta-Analysis

Nov 2026 · Circulation · 0 citations

Abstract

Background: The optimal dose and type of direct oral anticoagulant for extended secondary prevention of venous thromboembolism after completion of initial anticoagulant therapy remain uncertain. Balancing recurrent thromboembolic risk reduction against bleeding risk is particularly challenging during extended treatment. We performed a Bayesian network meta-analysis to compare the efficacy and safety of different direct oral anticoagulant dose strategies during extended anticoagulation. Methods: A systematic search of major electronic databases and trial registries identified randomized controlled trials evaluating anticoagulation strategies for secondary prevention of venous thromboembolism (VTE) in patients completing ≥6 months of anticoagulant therapy. Eligible studies compared placebo, aspirin 100 mg, apixaban (2.5 mg twice daily [BID], 5 mg BID), and rivaroxaban (10 mg once daily [OD], 20 mg OD) in patients with previous deep vein thrombosis (DVT) and/or pulmonary embolism (PE). Studies from inception through April 2026 were screened. Bayesian random-effects network meta-analysis estimated relative risks (RRs), 95% credible intervals (CrIs), and treatment rankings using surface under the cumulative ranking curve (SUCRA). Primary outcomes were recurrent VTE and recurrent DVT; secondary outcomes included major bleeding or clinically relevant non-major bleeding (MB/CRNMB). Results: Five randomized controlled trials comprising 8,369 participants were included. For recurrent DVT, rivaroxaban 10 mg OD ranked highest (SUCRA 71.18; RR 0.11; 95% CrI 0.00-7.03), followed by apixaban 2.5 mg BID (SUCRA 70.41; RR 0.12; 95% CrI 0.01-1.67) and apixaban 5 mg BID (SUCRA 62.25; RR 0.14; 95% CrI 0.01-2.03). For recurrent VTE, apixaban 2.5 mg BID ranked highest (SUCRA 66.89; RR 0.13; 95% CrI 0.00-17.95), followed by rivaroxaban 10 mg OD (SUCRA 63.12; RR 0.14; 95% CrI 0.00-281.63) and rivaroxaban 20 mg OD (SUCRA 59.21; RR 0.18; 95% CrI 0.00-41.40). Aspirin ranked lower (SUCRA 37.61). For MB/CRNMB, placebo ranked highest for safety (SUCRA 88.56), followed by apixaban 2.5 mg BID (SUCRA 78.06; RR 1.23; 95% CrI 0.27-5.47). Rivaroxaban 20 mg OD ranked lowest for safety (SUCRA 10.14). Wide CrIs indicated substantial uncertainty. Conclusions: Reduced-dose direct oral anticoagulant regimens generally demonstrated more favorable efficacy and safety rankings for extended secondary prevention of VTE, with apixaban 2.5 mg BID and rivaroxaban 10 mg OD showing favorable profiles across recurrent thrombotic outcomes. However, wide CrIs indicate substantial uncertainty, warranting further adequately powered randomized trials to define optimal anticoagulation strategies.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.